Publications
View AllTeclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
In patients with multiple myeloma who had received one to three previous lines of therapy, those in the teclistamab-daratumumab group had significantly longer progression-free s...
Affiliated Researchers
Institution Info
- Type
- facility
- Country
- CA
- Publications
- 4
- Citations
- 5,845
External Links
Identifiers
- ROR
- https://ror.org/00dpztj76